Class action lawsuit filed against Organogenesis has been dismissed.CANTON, Mass.--(BUSINESS WIRE)--March 14, 1996--Organogenesis or  gan·o·ge·net ic (-j -n t Inc. (AMEX: ORG) announced today that the class action lawsuit filed against the company alleging federal securities law violations has been dismissed. The dismissal was without prejudice, and no payment or compensation of any sort has been made to the plaintiff or his counsel in connection with the dismissal of this action. Organogenesis designs, develops and manufactures innovative medical therapeutics using living human cells and natural connective tissue connective tissue, supportive tissue widely distributed in the body, characterized by large amounts of intercellular substance and relatively few cells. The intercellular material, or matrix, is produced by the cells and gives the tissue its particular character. Connective tissue is diversified in function and may be divided into four categories according to the type of matrix. components. Organogenesis' tissue-engineered products, such as Graftskin are designed to promote the establishment and growth of new tissues that maintain, restore or improve biological function. Its product development focus includes wound care, urology, cardiovascular surgery and general surgery. CONTACT: Organogenesis, Canton Carol S. Hausner, 617/575-0898 X3007 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion